ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday
ImmunityBio, Inc. shares closed Friday down 12.1% at $6.45, having traded as high as $7.88 and as low as $6.43 amid heavy volume.
CRISPR Therapeutics stock drops 9% after CEO sale filing — what CRSP investors watch next week
CRISPR Therapeutics AG shares dropped 8.7% on Friday, ending the day at $55.52. The stock moved sharply between $61.01 and $55.07 during a choppy session that saw roughly 2.4 million shares change hands.
Gilead stock jumps again as Trodelvy-Keytruda breast cancer data hit NEJM
Gilead Sciences shares climbed $4.59, or 3.5%, to $135.73 in Friday afternoon trading, building on a strong two-day surge and hitting new highs. The stock started the day at $131.26 and fluctuated between $130.65 and $136.26, with roughly 8.8 million shares traded.
Revelation Biosciences (REVB) stock ticks up premarket after FDA lays out Gemini trial path
Revelation Biosciences shares climbed roughly 2% in premarket Friday, adding to a rollercoaster week for the lightly traded biotech. Investors were reacting to the company’s newest regulatory update. The stock last changed hands near $0.85.
CRISPR Therapeutics stock in focus as shares cool premarket after 11% surge and CEO sale filing
CRISPR Therapeutics AG shares slipped about 0.5% to $60.51 in premarket trading on Friday, following a sharp 11.1% gain the previous day. The stock closed at $60.81 on Thursday after hitting an intraday high of $60.86 and seeing over 3.4 million shares change hands. Investors were reacting to an insider-sale filing.
Regencell Bioscience stock price jumps again: RGC up 16% premarket after 40% surge
Regencell Bioscience Holdings Ltd shares climbed 16.3% to $35.77 in premarket trading Friday, building on a steep rise from the day before.
CSL share price rises on ASX as U.S. vaccine policy shifts rattle the sector
CSL Ltd shares closed Friday 0.7% higher at A$179.62, building on Thursday’s 1.3% rise. The stock fluctuated between A$179.33 and A$180.80 during the session, with roughly 1.01 million shares traded.
Moderna (MRNA) stock jumps after-hours as CEO signals pullback in new vaccine trials
Moderna shares surged 4.2% to $51.87 in after-hours trading Thursday, following an earlier jump of about 11% to $55.17 on heavy volume—more than 34 million shares changed hands. CEO Stephane Bancel told Bloomberg TV the company won’t invest in new late-stage vaccine trials, pointing to growing resistance from U.S. officials. He cautioned that the U.S. market is becoming less dependable. “You cannot make a return on investment if you don’t have access to the U.S. market,” Bancel said.
GRAIL stock jumps as Galleri outlook and FDA filing timeline come back into focus
Shares of GRAIL surged 13.2% to $114.41 Thursday afternoon, topping out at an intraday high of $118.50 earlier in the session.
Thermo Fisher stock price today: TMO steadies near a 52-week high ahead of Jan. 29 earnings
Thermo Fisher Scientific Inc shares rose $2.03, or 0.3%, to $638.33 on Thursday afternoon, after briefly climbing as high as $643.66 earlier in the session.
Regencell Bioscience (RGC) stock price jumps 37% again as the latest swing hits Nasdaq screens
Shares of Regencell Bioscience Holdings Limited jumped roughly 37% to $29.98 in afternoon trading Thursday, rebounding sharply from earlier dips. The stock swung between $20.91 and $30.78, with around 1 million shares changing hands by 1:19 p.m. EST.
Moderna stock jumps again as Merck cancer vaccine data keeps MRNA rally running
Moderna shares climbed 7.7% to $53.65 Thursday morning, extending gains fueled by fresh long-term data on its experimental personalized cancer vaccine, created in partnership with Merck.
Vertex stock jumps 4% as earnings date nears — what traders watch next for VRTX
Vertex Pharmaceuticals shares jumped 4.31%, closing Wednesday at $461.14 and marking their third straight session of gains. Trading volume climbed past the stock’s 50-day average. VRTX outperformed peers like AbbVie, Krystal Biotech, and Arcturus Therapeutics, while the S&P 500 and Dow each gained over 1%.
Moderna stock (MRNA) steadies in premarket after 16% surge on Merck cancer-vaccine data
Moderna shares were flat at $49.81 in premarket trading on Thursday, after the stock jumped 15.8% in the previous session.
ImmunityBio stock price dips today as IBRX cools off after FDA resubmission update
ImmunityBio shares dropped roughly 2% to $6.35 in Wednesday afternoon trading, as investors pared back after the biotech’s recent regulatory update. The stock swung between $5.74 and $6.64, with around 67 million shares changing hands.
Corvus Pharmaceuticals stock whipsaws: CRVS slides after $150 million offering follows eczema data surge
Shares of Corvus Pharmaceuticals, Inc. dropped nearly 8%, slipping to $19.68 in premarket trading Wednesday. The decline follows the company's announcement of an underwritten public offering worth $150 million in common stock and pre-funded warrants. These warrants let investors lock in shares now by paying most of the price upfront, with the option to buy later. Jefferies and Goldman Sachs are heading the deal, which also includes a 30-day over-allotment option allowing underwriters to purchase an extra $22.5 million in shares.
Merck stock barely budges after five-year Moderna vaccine data keeps Keytruda trade in play
Merck & Co shares held steady on Tuesday following news that the company's personalized cancer vaccine, developed with Moderna, continued to lower the risk of melanoma recurrence and death when used alongside Keytruda. By 2:02 p.m. EST, Merck was down just 0.01% at $108.82, with the stock fluctuating between $107.06 and $109.11.
Qiagen stock price jumps nearly 16% as Bloomberg report revives sale talk
Qiagen’s shares in the U.S. surged 15.9% to $55.13 on Tuesday after reports surfaced that the molecular diagnostics firm is exploring strategic options, including a potential sale, amid renewed takeover interest. The term often signals major moves like a sale; Qiagen has yet to comment.
ImmunityBio stock jumps before the open after FDA outlines next step for ANKTIVA filing
ImmunityBio shares rose about 27% to $7 in premarket trading on Tuesday, with about 4.1 million shares changing hands, after the company said it had made progress with the U.S. Food and Drug Administration on a path to revive a label-expansion push for its bladder cancer treatment ANKTIVA.
ImmunityBio stock set for volatile week after ANKTIVA sales jump and new trial update
ImmunityBio shares jumped on Friday and look set to remain in the spotlight when U.S. markets open again. The company revealed a steep rise in preliminary sales for its bladder cancer immunotherapy ANKTIVA, alongside a quicker-than-anticipated pace in trial enrollments.
TechStock² Updates
